vs

Side-by-side financial comparison of MOGU Inc. (MOGU) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

RECURSION PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($35.5M vs $19.5M, roughly 1.8× MOGU Inc.). MOGU Inc. runs the higher net margin — -44.3% vs -304.2%, a 260.0% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs -12.4%). MOGU Inc. produced more free cash flow last quarter ($-10.7M vs $-47.3M).

Mogu Mogu is a brand of fruit-flavoured drink with pieces of nata de coco, produced by Thailand-based Sappe Public Company Limited and exported to many international markets, especially South Korea, the Philippines, Indonesia and France.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

MOGU vs RXRX — Head-to-Head

Bigger by revenue
RXRX
RXRX
1.8× larger
RXRX
$35.5M
$19.5M
MOGU
Growing faster (revenue YoY)
RXRX
RXRX
+694.1% gap
RXRX
681.7%
-12.4%
MOGU
Higher net margin
MOGU
MOGU
260.0% more per $
MOGU
-44.3%
-304.2%
RXRX
More free cash flow
MOGU
MOGU
$36.6M more FCF
MOGU
$-10.7M
$-47.3M
RXRX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MOGU
MOGU
RXRX
RXRX
Revenue
$19.5M
$35.5M
Net Profit
$-8.6M
$-108.1M
Gross Margin
0.0%
59.8%
Operating Margin
-71.6%
-304.8%
Net Margin
-44.3%
-304.2%
Revenue YoY
-12.4%
681.7%
Net Profit YoY
-5.0%
39.6%
EPS (diluted)
$0.00
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MOGU
MOGU
RXRX
RXRX
Q4 25
$35.5M
Q3 25
$5.2M
Q2 25
$19.2M
Q1 25
$19.5M
$14.7M
Q4 24
$4.5M
Q3 24
$26.1M
Q2 24
$14.4M
Q1 24
$22.2M
$13.8M
Net Profit
MOGU
MOGU
RXRX
RXRX
Q4 25
$-108.1M
Q3 25
$-162.3M
Q2 25
$-171.9M
Q1 25
$-8.6M
$-202.5M
Q4 24
$-178.9M
Q3 24
$-95.8M
Q2 24
$-97.5M
Q1 24
$-8.2M
$-91.4M
Gross Margin
MOGU
MOGU
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
0.0%
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
0.0%
19.1%
Operating Margin
MOGU
MOGU
RXRX
RXRX
Q4 25
-304.8%
Q3 25
-3327.6%
Q2 25
-916.8%
Q1 25
-71.6%
-1297.9%
Q4 24
-4042.4%
Q3 24
-377.1%
Q2 24
-697.4%
Q1 24
-49.4%
-698.4%
Net Margin
MOGU
MOGU
RXRX
RXRX
Q4 25
-304.2%
Q3 25
-3135.3%
Q2 25
-894.2%
Q1 25
-44.3%
-1373.3%
Q4 24
-3935.5%
Q3 24
-367.5%
Q2 24
-676.6%
Q1 24
-37.0%
-662.4%
EPS (diluted)
MOGU
MOGU
RXRX
RXRX
Q4 25
$-0.17
Q3 25
$-0.36
Q2 25
$-0.41
Q1 25
$0.00
$-0.50
Q4 24
$-0.56
Q3 24
$-0.34
Q2 24
$-0.40
Q1 24
$0.00
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MOGU
MOGU
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$52.3M
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$70.1M
$1.1B
Total Assets
$118.3M
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MOGU
MOGU
RXRX
RXRX
Q4 25
$743.3M
Q3 25
$659.8M
Q2 25
$525.1M
Q1 25
$52.3M
$500.5M
Q4 24
$594.4M
Q3 24
$427.6M
Q2 24
$474.3M
Q1 24
$58.2M
$296.3M
Total Debt
MOGU
MOGU
RXRX
RXRX
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
MOGU
MOGU
RXRX
RXRX
Q4 25
$1.1B
Q3 25
$1.0B
Q2 25
$919.1M
Q1 25
$70.1M
$933.9M
Q4 24
$1.0B
Q3 24
$524.6M
Q2 24
$584.4M
Q1 24
$81.5M
$401.2M
Total Assets
MOGU
MOGU
RXRX
RXRX
Q4 25
$1.5B
Q3 25
$1.4B
Q2 25
$1.3B
Q1 25
$118.3M
$1.3B
Q4 24
$1.4B
Q3 24
$726.5M
Q2 24
$775.9M
Q1 24
$130.0M
$557.8M
Debt / Equity
MOGU
MOGU
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MOGU
MOGU
RXRX
RXRX
Operating Cash FlowLast quarter
$-9.4M
$-46.1M
Free Cash FlowOCF − Capex
$-10.7M
$-47.3M
FCF MarginFCF / Revenue
-55.2%
-133.1%
Capex IntensityCapex / Revenue
7.1%
3.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MOGU
MOGU
RXRX
RXRX
Q4 25
$-46.1M
Q3 25
$-117.4M
Q2 25
$-76.4M
Q1 25
$-9.4M
$-132.0M
Q4 24
$-115.4M
Q3 24
$-59.2M
Q2 24
$-82.2M
Q1 24
$-5.6M
$-102.3M
Free Cash Flow
MOGU
MOGU
RXRX
RXRX
Q4 25
$-47.3M
Q3 25
$-117.6M
Q2 25
$-79.6M
Q1 25
$-10.7M
$-133.8M
Q4 24
$-116.7M
Q3 24
$-63.8M
Q2 24
$-83.4M
Q1 24
$-18.6M
$-109.0M
FCF Margin
MOGU
MOGU
RXRX
RXRX
Q4 25
-133.1%
Q3 25
-2272.5%
Q2 25
-413.9%
Q1 25
-55.2%
-907.4%
Q4 24
-2567.7%
Q3 24
-244.6%
Q2 24
-578.5%
Q1 24
-84.0%
-789.9%
Capex Intensity
MOGU
MOGU
RXRX
RXRX
Q4 25
3.5%
Q3 25
4.7%
Q2 25
16.4%
Q1 25
7.1%
12.4%
Q4 24
28.6%
Q3 24
17.5%
Q2 24
8.2%
Q1 24
58.7%
48.2%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons